10-Q: Philip Morris International Q1 2026 Earnings Report

Philip Morris International reported a 9.1% increase in net revenues to $10.1 billion for Q1 2026, driven by strong performance in its International Smoke-Free segment, though diluted EPS saw a decline.

Summary

• Philip Morris International (PMI) reported net revenues of $10.1 billion for the first quarter of 2026, an increase of 9.1% compared to the same period in 2025.
• Diluted Earnings Per Share (EPS) decreased by 9.3% to $1.56, primarily due to unfavorable fair value adjustments for equity security investments and restructuring charges.
• The International Smoke-Free segment showed robust growth with a 24.7% increase in net revenues, driven by higher Heat-Not-Burn (HTU) and e-vapor volumes and pricing.
• The International Combustibles segment saw a 6.8% increase in net revenues, supported by favorable pricing, though volume/mix was impacted by distribution term restructurings.
• The U.S. segment experienced a significant 30.8% decrease in net revenues, attributed to lower ZYN volumes and challenging price comparisons.
• Net cash used in operating activities was $399 million, an unfavorable variance from the prior year, primarily due to lower currency-neutral net earnings and working capital fluctuations.
• Capital expenditures were $353 million, mainly for smoke-free product manufacturing capacity, with full-year expectations between $1.4 billion and $1.6 billion.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as mixed, with strong top-line growth in smoke-free products offset by a decline in U.S. segment performance and a decrease in diluted EPS, indicating some operational headwinds.

Positives

• Net revenues increased by 9.1% to $10.1 billion, driven by a 2.7% increase on a currency-neutral basis.
• International Smoke-Free segment net revenues grew by 24.7% (15.8% currency-neutral), with strong performance in HTU and e-vapor volumes and pricing.
• International Combustibles segment net revenues increased by 6.8% (1.0% currency-neutral), supported by favorable pricing.
• Gross profit increased by 10.1% (3.8% currency-neutral).
• Operating income increased by 9.8% (0.2% currency-neutral).
• The company expects full-year 2026 capital expenditures to be between $1.4 billion and $1.6 billion, predominantly supporting the smoke-free business.
• The FDA renewed exposure modification orders for IQOS products in April 2026, with an expiration date in April 2031.
• All 20 ZYN nicotine pouch varieties received FDA authorization in January 2025, with the FDA concluding they pose lower risks than cigarettes.

Negatives

• Diluted EPS decreased by 9.3% to $1.56, with a 19.8% decrease excluding favorable currency impacts.
• U.S. segment net revenues decreased by 30.8% (31.6% currency-neutral), primarily due to lower ZYN volumes and challenging price comparisons.
• U.S. smoke-free product shipment volume decreased by 21.2%, with ZYN shipments declining by 23.5%.
• Net cash used in operating activities was $399 million, compared to $350 million in the prior year.
• Equity investments and securities (income)/loss net was a loss of $403 million in 2026 compared to income of $205 million in 2025, primarily due to unfavorable fair value adjustments for equity security investments.
• Restructuring charges of $24 million were recorded in Q1 2026 related to U.S. footprint optimization initiatives.
• The German fiscal regulation imposing an additional excise tax on heated tobacco products (HTPs) continues to negatively impact net revenues, with an appeal pending.

Risks

• Regulatory restrictions on products, including formulation, packaging, marketing, and sales, could reduce competitiveness or ban products.
• Fiscal challenges such as excessive excise tax increases and discriminatory tax structures are expected to continue.
• Illicit trade in tobacco and nicotine-containing products, including counterfeit, contraband, and other illicit products, poses a risk.
• Intense competition, including unfair competition from non-tax-paid volume, is a significant factor.
• Legal challenges, including pending and threatened litigation related to tobacco and nicotine products, could materially affect profitability and liquidity.
• The company faces risks related to the commercialization and supply of its smoke-free products, including potential regulatory actions and consumer adoption rates.
• The company's business, results of operations, cash flows, and financial position may be adversely impacted by the continuation and consequences of the war in Ukraine.
• Cybersecurity incidents or attacks against information technology networks and systems could adversely impact business and operations.
• Failure to comply with privacy, data, artificial intelligence, and information security laws could result in reputational harm and legal liability.
• The research, development, and commercialization of non-recreational cannabinoid products are subject to legal, regulatory, and reputational risks.
• The company may be unable to adequately protect its intellectual property rights, and disputes relating to intellectual property could harm its business.

Future Outlook

For the full year 2026, PMI expects a broadly stable total shipment volume for cigarettes and smoke-free products, with high-single digit growth for smoke-free products and a cigarette shipment volume decline of around 3%. The company estimates its effective tax rate for 2026 to be around 21.5%, excluding discrete tax events. PMI expects total capital expenditures in 2026 to be between $1.4 billion and $1.6 billion, predominantly supporting the smoke-free business.

Management Comments

• "During the quarter, net revenues increased by 9.1%. Net revenues, excluding currency, increased by 2.7%, mainly reflecting: a favorable pricing variance mainly driven by International Combustibles; partly offset by an unfavorable volume/mix/other, mainly driven by lower International Combustibles and U.S. volumes, notwithstanding higher International Smoke-Free volumes."
• "The favorable impact of $0.18 per share from currency over the comparable 2025 period primarily results from the fluctuations of the U.S. dollar, especially against the Euro and Russian ruble, partly offset by the Japanese yen and Swiss franc."
• "The increase in diluted EPS of $0.03 from our operations in the table above was due primarily to the following: International Smoke-Free segment: Favorable volume/mix/other and favorable pricing; International Combustibles segment: Favorable pricing, partly offset by unfavorable volume/mix/other, including the favorable impact related to the restructuring of distribution terms in certain markets this quarter; U.S. segment: Unfavorable volume/mix/other, unfavorable pricing (mainly driven by increased consumer promotions) and higher manufacturing costs; and Higher marketing, administration and research costs."
• "Our smoke-free business now operating at scale across our regions, including growth from our U.S. business, PMI has implemented an evolved organizational model with two primary business units: International and U.S."

Industry Context

StockSavvy.ai notes that Philip Morris International's performance reflects broader industry trends, with a continued shift towards smoke-free products, as evidenced by the significant growth in the International Smoke-Free segment. However, the decline in the U.S. segment, particularly for ZYN, highlights market-specific challenges and competitive pressures within the oral nicotine pouch category. The company's ongoing investment in smoke-free product development and commercialization, alongside its strategic focus on transitioning away from cigarettes, aligns with the industry's long-term trajectory.

Comparison to Industry Standards

• PMI's net revenue growth of 9.1% in Q1 2026 outpaces the general consumer staples sector growth, but specific segment performance varies significantly.
• The 24.7% growth in the International Smoke-Free segment is a strong indicator of the company's success in transitioning its portfolio, a trend observed across leading tobacco companies investing heavily in reduced-risk products.
• The decline in the U.S. segment, particularly for ZYN, contrasts with the overall growth of the U.S. nicotine pouch market reported by some industry analysts, suggesting potential market share challenges or inventory adjustments for PMI.
• The company's effective tax rate of 18.5% is within the typical range for large multinational corporations, though specific tax impacts from international operations and financing can cause fluctuations.

Legal Proceedings

• Ongoing litigation related to combustible tobacco products, including health care cost recovery cases in Brazil, Korea, and Nigeria.
• Litigation filed against PMI and subsidiaries related to ZYN nicotine pouches in the United States, alleging addiction, defective design, marketing to minors, and misrepresentation.
• A case in Italy involving alleged contravention of anti-corruption laws and disruption of trade freedom, with a civil claim for damages filed by British American Tobacco Italia S.p.a.
• Brazilian Tax Authority assessments for alleged underpayments of indirect taxes for fiscal years 2020, 2021, 2022, and 2023.
• Patent infringement actions filed by FTKK against Sojitz concerning TEREA and SENTIA consumables in Japan.
• A lawsuit filed by the City of Baltimore alleging violations of its Consumer Protection Ordinance related to ZYN marketing.
• A case filed in Connecticut alleging addiction to nicotine from ZYN use, with claims for violations of New York General Business Law.
• A case filed in Maryland alleging violations of the City of Baltimore's Consumer Protection Ordinance related to ZYN marketing.
• A case filed in Connecticut alleging misrepresentation of ZYN as tobacco-free and misleading advertising.

Related Party Transactions

• Net revenues from related parties (Megapolis Group and Others) were $1,185 million for the three months ended March 31, 2026.
• Expenses with related parties (Others) were $96 million for the three months ended March 31, 2026.
• Receivables from related parties (Megapolis Group and Others) totaled $996 million as of March 31, 2026.
• Other assets related to related parties were $82 million as of March 31, 2026.
• Payables to related parties (Others) were $43 million as of March 31, 2026.
• PMI holds a 23% equity interest in JSC TK Megapolis, its distributor in Russia, with a carrying value of $307 million as of March 31, 2026.
• PMI holds a 49% equity interest in Emirati Investors-TA (FZC) and an indirect economic interest in Eastern Company in Egypt.
• PMI guarantees certain credit facilities and repayment of bank loan liabilities for its investment in Eastern Company, up to $385 million.

Stakeholder Impact

• Shareholders may be impacted by the decrease in diluted EPS and the ongoing legal challenges, although the growth in smoke-free products offers a positive long-term outlook.
• Employees may be affected by the U.S. footprint optimization initiatives, which include office closures and facility consolidation.
• Suppliers may experience changes in demand due to shifts in product mix and potential disruptions from geopolitical events or trade policies.
• Creditors may be influenced by the company's debt levels and its ability to manage its financial obligations, with credit ratings being a key factor.

Next Steps

• Continue to develop and commercialize smoke-free products.
• Focus on the U.S. market for IQOS device roll-out.
• Monitor and manage the appeal of the German fiscal regulation on HTPs.
• Continue to manage the legal proceedings related to ZYN nicotine pouches.
• Implement U.S. footprint optimization initiatives, including office closures and facility consolidation.

Key Dates

Recommendation

While PMI demonstrates strong growth in its core smoke-free business and has secured key regulatory approvals, the decline in U.S. segment performance, increased operating cash usage, and significant ongoing legal and regulatory risks warrant a cautious approach. The company's ability to navigate these challenges and fully capitalize on its smoke-free transition will be critical for future performance.

Keywords

Philip Morris International, PMI, 10-Q, Quarterly Report, Smoke-Free Products, Heat-Not-Burn, HTU, ZYN, IQOS, Financial Results, Net Revenues, Earnings Per Share, SEC Filing